Fundraising FoxSymbiomix Therapeutics
Newark, US · Founded 2012 · Delaware LLC · 4 known investors
Find your way into Symbiomix Therapeutics
Sign up to see every warm intro you have to Symbiomix Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Symbiomix Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Board
RG
KV
TB
BA
Ben AuspitzBoard director
KD
Karen DawesBoard director
Investors · 4
F-Prime CapitalreportedCambridge · $3M – $10M
How we know: funding news · Not right? Tell us
HBM Healthcare InvestmentsreportedZug
How we know: funding news · Not right? Tell us
HBM PartnersreportedZug · $5M – $50M
How we know: funding news · Not right? Tell us
OrbiMedreportedNew York · $1M – $75Mvia Klaus Veitinger · board
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$25.5M disclosed across 2 rounds · 2013–2016
▶$6MraisedMay 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$6MraisedMay 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rishi GuptaDirector
- Robert JacksExecutive Officer
- Karen DawesDirector
- Joseph AmpreyExecutive Officer
- Klaus VeitingerDirector
- Thomas BeckDirector
- Ben AuspitzDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
▶$19.5MraisedJul 2014 · 5 investors · PharmaceuticalsRule 506(c)
▶$19.5MraisedJul 2014 · 5 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Robert JacksExecutive Officer, Director
- Thomas BeckDirector
- Joseph AmpreyExecutive Officer
- Ben AuspitzDirector
- Rishi GuptaDirector
- Klaus VeitingerDirector
- Offering amount
- $32.5M
- Amount sold
- $19.5M
- First sale
- May 2013
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Symbiomix Therapeutics's investors?
- Symbiomix Therapeutics's investors include F-Prime Capital, HBM Healthcare Investments, HBM Partners, OrbiMed.
- How much funding has Symbiomix Therapeutics raised?
- Symbiomix Therapeutics has disclosed $25.5M raised across 2 rounds.
- Where is Symbiomix Therapeutics headquartered?
- Symbiomix Therapeutics is headquartered in Newark, US.